To assess the associations of semaglutide with recurrent CUD, the study population included 8196 patients with T2D who had active medical encounters for T2D diagnosis in 12/20175/2021, were for the first time prescribed semaglutide or non-GLP1-1RA anti-diabetes medications during 12/20175/2021(index event), had a diagnosis of CUD on or before the index event, and had a diagnosis of at least one of obesity-associated comorbidities on or before the index event
served as site principal investigator for the clinical trial (he received no financial compensation, nor was there a financial relationship) and reports advisory/consulting fees and/or other support from Boehringer Ingelheim, Eli Lilly & Company, Guidotti Laboratories, Menarini Diagnostics, Novo Nordisk and Therascience Lignaform
The storage requirements for this compounded medication reflect the need to preserve both the semaglutide and cyanocobalamin components while preventing degradation, contamination, or other changes that could negatively affect the medication
Recent findings also suggest that Sema may influence neuroendocrine circuits involved in food-related stress regulation and energy homeostasis
Side effects typically improve over time with both medications